A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.
A 6-week, multicenter randomised, double-blind, double-blind, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients